MindMaze Therapeutics Holding SA operates as a commercial-stage biopharmaceutical and neurotechnology company in Asia, the United States, Switzerland, rest of Europe, and internationally. The company offers MindPod system, a supervised in-clinic neurorehabilitation system designed to initiate and intensify the recovery journey; MindMotion GO, which extends protocolized neurotherapeutics into outpatient and home settings; MindMotion Companion, an application that manages prescription, monitoring and documentation across MindMaze Therapeutics' neurotherapeutics ecosystem; and the patient app, a patient-facing mobile application, that supports clinic-to-home continuity by making prescribed therapy easy to follow outside the clinic. It also provides Izar hand therapy device which supports fine motor rehabilitation; Physilog sensor, a wearable inertial sensing device designed to quantify human movement; toaprun, a training for Parkinson's therapy-reimagined through play. The company was founded in 2012 and is headquartered in Geneva, Switzerland.…
MindMaze Therapeutics gibt Finanzierung in Höhe von 4 Millionen CHF bekannt
MindMaze Therapeutics Holding (SWX: MMTX) is listed on the SIX Swiss Exchange, where its shares trade in CHF. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 10 employees.
The shares were at 0.1290 CHF on 20 November 2026. Its 52-week range is 0.1228 CHF to 2.990 CHF: the price is 95.7% below the high and 5.0% above the low.
Its market capitalisation is 21.93M CHF.
MindMaze Therapeutics Holding reports return on equity of -25.8%.
It holds more cash than debt, a net cash position of 5.30M CHF. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health.
No upcoming events tracked.